Silence Therapeutics plc (OTCMKTS:SLNCF) Stock Short Interest Report for October

Silence Therapeutics plc (OTCMKTS:SLNCF) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totaling 136 shares, a decrease of 94.2% from the September 30th total of 2,350 shares. Based on an average daily volume of 473 shares, the short-interest ratio is currently 0.3 days.

Silence Therapeutics Stock Performance

Shares of SLNCF remained flat at $6.37 during midday trading on Monday. The stock has a fifty day simple moving average of $4.42 and a 200-day simple moving average of $2.49. Silence Therapeutics has a 12-month low of $1.06 and a 12-month high of $6.38.

About Silence Therapeutics

Silence Therapeutics plc is a biotechnology company focused on developing medicines that selectively silence disease-associated genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to create potential treatments for cardiovascular, hematologic and other serious diseases.

Silence’s proprietary mRNAi GOLD platform is designed to deliver small interfering RNA (siRNA) medicines to the liver using GalNAc conjugation. Its pipeline has included zerlasiran (formerly SLN360), an investigational therapy intended to reduce production of lipoprotein(a), a genetically determined cardiovascular risk factor, and divesiran (formerly SLN124), an investigational treatment designed to regulate iron biology through suppression of the TMPRSS6 gene.